-
Mashup Score: 16
Long-term treatment with KarXT was associated with continued improvements in symptoms of schizophrenia across all efficacy measures at 52 weeks More than 75% of participants achieved >30% improvement in symptoms from baseline, as measured by the Positive and Negative Syndrome Scale (PANSS) total score, at one year Participants previously on placebo in acute trials experienced significant reduction of symptoms beginning at week two and maintained throughout treatment Bristol Myers Squibb (NYSE: BMY) today announced new interim results from the Phase 3 EMERGENT-4 open-label extension trial evaluating the long-term efficacy, safety and tolerability of KarXT (xanomeline-trospium) in adults with schizophrenia. Long-term efficacy data from the trial were presented in a poster titled, “Maintenance of Efficacy of KarXT (Xanomeline and Trospium) in Schizophrenia” (Poster F264) at the Annual Congress of the Schizophrenia International Research Society (SIRS) being held April 3-7, 2024, in
Source: news.bms.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 20
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial, with a 51% reduction in risk of disease progression or death and a well-established safety profile Expanded approval brings this personalized CAR T cell therapy to more patients with relapsed or refractory multiple myeloma earlier in their treatment journey as a one-time infusion offering meaningful treatment-free intervals when responding to therapy Abecma is now approved in the U.S., Japan, Switzerland and the EU for earlier use for triple-class exposed relapsed and/or refractory multiple myeloma, underscoring BMS’ commitment to delivering Abecma globally, with consistently high manufacturing success rates and continuous increases in capacity Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq: TSVT) have announced that on April 4, 2024, the U.S. Food and Drug Administration (FDA) approved Abecma® (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with
Source: news.bms.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 20
Approval of Reblozyl is based on head-to-head, pivotal Phase 3 COMMANDS study, in which Reblozyl nearly doubled the percentage of patients achieving transfusion independence and hemoglobin increase, along with increased durability compared to epoetin alfa This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia and the first therapy to demonstrate superior efficacy vs. epoetin alfa in LR-MDS Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has expanded approval of Reblozyl® (luspatercept) to include the first-line treatment of adult patients with transfusion-dependent anemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS). This approval of Reblozyl covers all EU member states.* “With this approval for Reblozyl as a first-line treatment for anemia in adults with lower-risk MDS, more patients in the EU will have the potential to become transfusion
Source: news.bms.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 6Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals - 2 month(s) ago
Company builds on its strengths to advance patient access, product innovation, culture and inclusion and diversity Bristol Myers Squibb (NYSE: BMY) today published its 2023 Environmental, Social, and Governance (ESG) Report detailing the company’s meaningful progress, evolved strategy, and aspirational goals toward its ESG efforts. The company’s ESG strategy is embedded in its mission to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. “For more than 130 years, BMS has enabled positive change for our patients around the world. As we navigate an increasingly complex global landscape, our ESG strategy has never been more important to driving long-term business value and fulfilling our purpose,” said Christopher Boerner , Ph.D., Board Chair Chief Executive Officer, Bristol Myers Squibb. “We recognize ESG is a journey of continuous improvement, and our entire team is committed to advancing sustainability.” In 2023, BMS conducted a
Source: news.bms.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 32
Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Bristol Myers Squibb (NYSE: BMY) today announced that the pivotal Phase 3 KRYSTAL-12 study, evaluating KRAZATI® (adagrasib) as a monotherapy in patients with pretreated locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation, met the primary endpoint of progression-free survival (PFS) and the key secondary endpoint of overall response rate (ORR) as assessed by Blinded Independent Central Review (BICR) at final analysis for these endpoints. The study remains ongoing to assess the additional key secondary endpoint of overall survival. Results of the confirmatory trial showed that KRAZATI demonstrated a statistically significant and clinically meaningful benefit in PFS and ORR compared to
Source: news.bms.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 16Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes - 2 month(s) ago
Company Awards $1.8M in Grants to Eight Organizations in Brazil, India, Thailand and the United Kingdom Bristol Myers Squibb (NYSE: BMY) today unveiled a $1.8 million initiative to advance health equity by addressing social determinants of health (SDoH) in four countries with underserved patient needs, including Brazil, India, Thailand, and the United Kingdom. The new health equity grants are an extension of the company’s broader long-term commitment to invest $150M in health equity by 2025 . Inequities in healthcare systems present a unique global challenge, with some studies suggesting that SDoH factors account for up to 50% of health outcomes within the United States. 1 The World Health Organization (WHO) defines SDoH as non-medical factors that influence health outcomes, such as: income and social status, education, physical environment, social support networks, genetics, health services and gender. As echoed by the United Nations Sustainable Development Goal #3 (Good Health
Source: news.bms.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 10
Analysis from a 10-month post-launch evaluation of the REMS Program finds 2.8% incidence of LVEF <50% in over 1500 patients, strengthening the safety profile of CAMZYOS® (mavacamten) for NYHA class II-III obstructive hypertrophic cardiomyopathy Real-world data reaffirm therapeutic value and treatment benefit of CAMZYOS in improving cardiac symptoms and NYHA class in patients with obstructive hypertrophic cardiomyopathy Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data at the American College of Cardiology (ACC) Annual Scientific Session Expo, taking place April 6-8, 2024 in Atlanta, Georgia. “The therapeutic benefit of CAMZYOS in real-world practice, demonstrated by our data at ACC, builds on the well-established clinical program and further underscores the importance of this transformational medicine which is the first and only approved cardiac myosin inhibitor. With thousands of patients around the world treated to date, CAMZYOS is redefining the
Source: news.bms.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 21
Abecma demonstrated superiority over standard regimens in the Phase 3 KarMMa-3 trial, with a 51% reduction in risk of disease progression or death and a well-established safety profile with mostly low-grade and transient occurrences of cytokine release syndrome and neurotoxicity Approval reinforces Bristol Myers Squibb’s commitment to bring the transformative potential of cell therapy into earlier lines of treatment Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has granted approval to Abecma® (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. Abecma is the first chimeric antigen receptor (CAR) T cell immunotherapy approved in the European Union (EU) for use in earlier lines of
Source: news.bms.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 22
Opdivo plus Yervoy demonstrates statistically significant and clinically meaningful improvement in overall survival compared to investigator’s choice of sorafenib or lenvatinib Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -9DW trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for patients with advanced hepatocellular carcinoma (HCC) who have not received prior systemic therapy met its primary endpoint of improved overall survival (OS) compared to investigator’s choice of sorafenib or lenvatinib at a pre-specified interim analysis. The dual immunotherapy combination of Opdivo plus Yervoy demonstrated a statistically significant and clinically meaningful improvement in OS compared to investigator’s choice of sorafenib or lenvatinib. The safety profile for the combination of Opdivo plus Yervoy remained consistent with previously reported data and was manageable with established protocols, with no new safety signals
Source: news.bms.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 11Bristol Myers Squibb and Ted Danson Empower Those with Plaque Psoriasis to Take Action in “SO, Have You Found It?” Campaign - 2 month(s) ago
Award-winning actor Ted Danson, who lives with plaque psoriasis, teams up with Bristol Myers Squibb for the inspiring “ SO, Have You Found It? ” campaign. This initiative spotlights the resilience of around two million Americans with moderate to severe plaque psoriasis, aiming to amplify their voices, underscoring the strength of their inner vibe, the “it” factor that makes someone uniquely them. i The campaign signifies a shift in dialogue from the challenges associated with the condition to empowering individuals to confidently navigate their plaque psoriasis in partnership with their dermatologists. Actor Ted Danson and SOTYKTU patient Emily both living with moderate to severe plaque psoriasis. (Photo: Bristol Myers Squibb) Expanding the “Found It” Conversation “Navigating plaque psoriasis is both deeply personal and often challenging for many patients,” acknowledged Carlos Dortrait, senior vice president and general manager of U.S. Immunology and Neuroscience at Bristol Myers
Source: news.bms.comCategories: General Medicine News, PayerTweet
#MEDIA: Today, we presented interim long-term efficacy results from the Phase 3 EMERGENT-4 trial in adults living with schizophrenia at #SIRS2024. https://t.co/4Ml20N32rZ https://t.co/5S8yUgGQbt